U.S. Markets open in 4 hrs 28 mins
  • S&P Futures

    4,350.75
    +9.25 (+0.21%)
     
  • Dow Futures

    34,081.00
    +26.00 (+0.08%)
     
  • Nasdaq Futures

    14,227.50
    +69.00 (+0.49%)
     
  • Russell 2000 Futures

    1,969.70
    -3.00 (-0.15%)
     
  • Crude Oil

    87.38
    +0.03 (+0.03%)
     
  • Gold

    1,815.30
    -14.40 (-0.79%)
     
  • Silver

    23.35
    -0.45 (-1.90%)
     
  • EUR/USD

    1.1201
    -0.0044 (-0.3920%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • Vix

    30.43
    -0.73 (-2.34%)
     
  • GBP/USD

    1.3430
    -0.0033 (-0.2417%)
     
  • USD/JPY

    115.0150
    +0.3550 (+0.3096%)
     
  • BTC-USD

    36,540.63
    -1,175.91 (-3.12%)
     
  • CMC Crypto 200

    833.65
    -22.16 (-2.59%)
     
  • FTSE 100

    7,489.52
    +19.74 (+0.26%)
     
  • Nikkei 225

    26,170.30
    -841.00 (-3.11%)
     

Senseonics to Participate in Upcoming November Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SENS

GERMANTOWN, Md., November 08, 2021--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in two upcoming investor conferences.

Stifel 2021 Virtual Healthcare Conference
Management will participate in a virtual fireside chat on Tuesday, November 16, 2021 at 8:40am ET.

Jefferies London Healthcare Conference
A presentation from management will be made available on Thursday, November 18, 2021 at 3:00am ET.

Interested parties may access these live and on-demand webcasts on the "Investors" section of the Company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005873/en/

Contacts

Senseonics Investor Relations Contact:
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
Investors@senseonics.com